RU2006102130A - Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов - Google Patents
Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов Download PDFInfo
- Publication number
- RU2006102130A RU2006102130A RU2006102130/04A RU2006102130A RU2006102130A RU 2006102130 A RU2006102130 A RU 2006102130A RU 2006102130/04 A RU2006102130/04 A RU 2006102130/04A RU 2006102130 A RU2006102130 A RU 2006102130A RU 2006102130 A RU2006102130 A RU 2006102130A
- Authority
- RU
- Russia
- Prior art keywords
- phenyl
- compound according
- amino
- treatment
- dione
- Prior art date
Links
- 230000002440 hepatic effect Effects 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 46
- -1 2-methylthioethyl Chemical group 0.000 claims 43
- 238000011282 treatment Methods 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 15
- 238000000034 method Methods 0.000 claims 15
- 238000004519 manufacturing process Methods 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 230000002265 prevention Effects 0.000 claims 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 238000011321 prophylaxis Methods 0.000 claims 7
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 5
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims 4
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 4
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 210000000936 intestine Anatomy 0.000 claims 3
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 238000008214 LDL Cholesterol Methods 0.000 claims 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 230000001906 cholesterol absorption Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000003054 hormonal effect Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 102000004311 liver X receptors Human genes 0.000 claims 2
- 108090000865 liver X receptors Proteins 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 230000004141 reverse cholesterol transport Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- YQQHQHXKODBEOZ-UHFFFAOYSA-N 1-(2-methoxyethyl)-3-(4-methylsulfanylanilino)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(SC)C=C1 YQQHQHXKODBEOZ-UHFFFAOYSA-N 0.000 claims 1
- YARVSNLAHFZJKN-UHFFFAOYSA-N 1-(2-methoxyethyl)-3-(4-morpholin-4-ylanilino)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC(C=C1)=CC=C1N1CCOCC1 YARVSNLAHFZJKN-UHFFFAOYSA-N 0.000 claims 1
- YDUSKSCVRROBON-UHFFFAOYSA-N 1-(furan-3-ylmethyl)-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=COC=C1 YDUSKSCVRROBON-UHFFFAOYSA-N 0.000 claims 1
- JDHWLVUZCIEPGC-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-(4-morpholin-4-ylanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=NC(N)=CC=C1CN1C(=O)C(C=2C=CC=CC=2)=C(NC=2C=CC(=CC=2)N2CCOCC2)C1=O JDHWLVUZCIEPGC-UHFFFAOYSA-N 0.000 claims 1
- XPAWGAHBNJTADB-UHFFFAOYSA-N 1-[(6-aminopyridin-3-yl)methyl]-3-[4-(difluoromethoxy)anilino]-4-phenylpyrrole-2,5-dione Chemical compound C1=NC(N)=CC=C1CN1C(=O)C(C=2C=CC=CC=2)=C(NC=2C=CC(OC(F)F)=CC=2)C1=O XPAWGAHBNJTADB-UHFFFAOYSA-N 0.000 claims 1
- CUEFJLIVXWUITG-UHFFFAOYSA-N 1-[[4-(dimethylamino)phenyl]methyl]-3-(4-methoxyanilino)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=C(N(C)C)C=C1 CUEFJLIVXWUITG-UHFFFAOYSA-N 0.000 claims 1
- VWDGCBRPFUNZBZ-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-(2-methylsulfanylethyl)-4-phenylpyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CCSC)C1=O VWDGCBRPFUNZBZ-UHFFFAOYSA-N 0.000 claims 1
- LGKWEWTVEPDUAV-UHFFFAOYSA-N 3-(4-methoxyanilino)-1-(3-methoxypropyl)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCCOC)C(=O)C=1NC1=CC=C(OC)C=C1 LGKWEWTVEPDUAV-UHFFFAOYSA-N 0.000 claims 1
- OYBLWUWJHPWMTA-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(2,2,2-trifluoroethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CC(F)(F)F)C1=O OYBLWUWJHPWMTA-UHFFFAOYSA-N 0.000 claims 1
- PIAPWUIDIJHWFZ-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(3,3,3-trifluoropropyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC1=C(C=2C=CC=CC=2)C(=O)N(CCC(F)(F)F)C1=O PIAPWUIDIJHWFZ-UHFFFAOYSA-N 0.000 claims 1
- WMNVVLNVJBKEMR-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-2-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CC=N1 WMNVVLNVJBKEMR-UHFFFAOYSA-N 0.000 claims 1
- UUADKLHVJWMDLF-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 UUADKLHVJWMDLF-UHFFFAOYSA-N 0.000 claims 1
- BWABNEHKDRQBPP-UHFFFAOYSA-N 3-(4-methoxyanilino)-4-phenyl-1-(pyridin-4-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=NC=C1 BWABNEHKDRQBPP-UHFFFAOYSA-N 0.000 claims 1
- CGAORHFPTNYUGA-UHFFFAOYSA-N 3-(4-morpholin-4-ylanilino)-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound O=C1C(C=2C=CC=CC=2)=C(NC=2C=CC(=CC=2)N2CCOCC2)C(=O)N1CC1=CC=CN=C1 CGAORHFPTNYUGA-UHFFFAOYSA-N 0.000 claims 1
- RPTBJJNNXVXBKM-UHFFFAOYSA-N 3-[(2-acetyl-1-benzofuran-5-yl)amino]-1-(2-methoxyethyl)-4-phenylpyrrole-2,5-dione Chemical compound O=C1N(CCOC)C(=O)C(NC=2C=C3C=C(OC3=CC=2)C(C)=O)=C1C1=CC=CC=C1 RPTBJJNNXVXBKM-UHFFFAOYSA-N 0.000 claims 1
- QNMXSSQGJHJCLI-UHFFFAOYSA-N 3-[(2-acetyl-1-benzofuran-5-yl)amino]-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound C=1C=C2OC(C(=O)C)=CC2=CC=1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 QNMXSSQGJHJCLI-UHFFFAOYSA-N 0.000 claims 1
- GRBPWTWSVBRHIQ-UHFFFAOYSA-N 3-[4-(difluoromethoxy)anilino]-1-(2-methoxyethyl)-4-phenylpyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(OC(F)F)C=C1 GRBPWTWSVBRHIQ-UHFFFAOYSA-N 0.000 claims 1
- DIGLAFAKZCPPOA-UHFFFAOYSA-N 3-[4-(difluoromethoxy)anilino]-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound C1=CC(OC(F)F)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 DIGLAFAKZCPPOA-UHFFFAOYSA-N 0.000 claims 1
- RAQFUEVZUPBBNT-UHFFFAOYSA-N 3-anilino-4-phenyl-1-(pyridin-3-ylmethyl)pyrrole-2,5-dione Chemical compound O=C1C(C=2C=CC=CC=2)=C(NC=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 RAQFUEVZUPBBNT-UHFFFAOYSA-N 0.000 claims 1
- DGYFPKIMHGNRES-UHFFFAOYSA-N 3-phenyl-1-(2,2,2-trifluoroethyl)-4-[4-(trifluoromethoxy)anilino]pyrrole-2,5-dione Chemical compound C=1C=CC=CC=1C=1C(=O)N(CC(F)(F)F)C(=O)C=1NC1=CC=C(OC(F)(F)F)C=C1 DGYFPKIMHGNRES-UHFFFAOYSA-N 0.000 claims 1
- NGJSBKOSAZGTJL-UHFFFAOYSA-N 3-phenyl-1-(pyridin-3-ylmethyl)-4-[4-(trifluoromethoxy)anilino]pyrrole-2,5-dione Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC(C1=O)=C(C=2C=CC=CC=2)C(=O)N1CC1=CC=CN=C1 NGJSBKOSAZGTJL-UHFFFAOYSA-N 0.000 claims 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005604 azodicarboxylate group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims 1
- PVYOHJFFADYDDE-UHFFFAOYSA-N ethyl 2-[3-(4-methoxyanilino)-2,5-dioxo-4-phenylpyrrol-1-yl]acetate Chemical compound C=1C=CC=CC=1C=1C(=O)N(CC(=O)OCC)C(=O)C=1NC1=CC=C(OC)C=C1 PVYOHJFFADYDDE-UHFFFAOYSA-N 0.000 claims 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- UGTDRLZDYHDNHS-UHFFFAOYSA-N methyl 4-[[3-(4-methoxyanilino)-2,5-dioxo-4-phenylpyrrol-1-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C(=O)C(C=2C=CC=CC=2)=C(NC=2C=CC(OC)=CC=2)C1=O UGTDRLZDYHDNHS-UHFFFAOYSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- FBPNLPUTIKFOLV-UHFFFAOYSA-N n-[4-[[1-(2-methoxyethyl)-2,5-dioxo-4-phenylpyrrol-3-yl]amino]phenyl]acetamide Chemical compound C=1C=CC=CC=1C=1C(=O)N(CCOC)C(=O)C=1NC1=CC=C(NC(C)=O)C=C1 FBPNLPUTIKFOLV-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 0 *C(C(*)C(N1)=O)C1=O Chemical compound *C(C(*)C(N1)=O)C1=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0316232.8 | 2003-07-11 | ||
| GBGB0316232.8A GB0316232D0 (en) | 2003-07-11 | 2003-07-11 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006102130A true RU2006102130A (ru) | 2007-08-20 |
Family
ID=27741983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006102130/04A RU2006102130A (ru) | 2003-07-11 | 2004-07-08 | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7432288B2 (enExample) |
| EP (1) | EP1646626B1 (enExample) |
| JP (1) | JP2007521312A (enExample) |
| KR (1) | KR20060035748A (enExample) |
| CN (1) | CN1823061A (enExample) |
| AR (1) | AR045721A1 (enExample) |
| AT (1) | ATE399777T1 (enExample) |
| AU (1) | AU2004255999B2 (enExample) |
| BR (1) | BRPI0412472A (enExample) |
| CA (1) | CA2532056A1 (enExample) |
| DE (1) | DE602004014773D1 (enExample) |
| ES (1) | ES2308204T3 (enExample) |
| GB (1) | GB0316232D0 (enExample) |
| IL (1) | IL172760A0 (enExample) |
| IS (1) | IS8293A (enExample) |
| MX (1) | MXPA06000414A (enExample) |
| MY (1) | MY135821A (enExample) |
| NO (1) | NO20060081L (enExample) |
| RU (1) | RU2006102130A (enExample) |
| SA (1) | SA04250204B1 (enExample) |
| TW (1) | TW200503691A (enExample) |
| UA (1) | UA82109C2 (enExample) |
| UY (1) | UY28408A1 (enExample) |
| WO (1) | WO2005005417A1 (enExample) |
| ZA (1) | ZA200600222B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1634877B1 (en) * | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
| US7505238B2 (en) * | 2005-01-07 | 2009-03-17 | Agnes Neves Woo | ESD configuration for low parasitic capacitance I/O |
| RU2007130152A (ru) | 2005-01-10 | 2009-02-20 | Астразенека Аб (Se) | Производные 1, 1-диоксидов изотиазол-3(2h)-онов в качестве модуляторов печеночных х-рецепторов |
| SE0500055D0 (sv) | 2005-01-10 | 2005-01-10 | Astrazeneca Ab | Therapeutic agents 3 |
| CA2640806A1 (en) * | 2006-04-28 | 2007-11-15 | Laboratorios Del Dr. Esteve, S.A. | Bicyclic tetrahydropyrrole compounds |
| KR101475088B1 (ko) | 2006-08-21 | 2014-12-23 | 제넨테크, 인크. | 아자-벤조티오페닐 화합물 및 사용 방법 |
| CN101456863B (zh) * | 2007-12-14 | 2012-04-25 | 华北制药集团新药研究开发有限责任公司 | Lxr激动剂及其制备方法和用途 |
| JP5615274B2 (ja) | 2008-07-01 | 2014-10-29 | ジェネンテック， インコーポレイテッド | Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法 |
| US8841462B2 (en) | 2008-07-01 | 2014-09-23 | Robert A. Heald | Bicyclic heterocycles as MEK kinase inhibitors |
| AU2011299703A1 (en) | 2010-09-07 | 2013-04-11 | Snu R&Db Foundation | Sesterterpene compounds and use thereof |
| JP2014500264A (ja) | 2010-12-03 | 2014-01-09 | アラーガン インコーポレイテッド | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規オキシム誘導体 |
| CN103354742A (zh) | 2010-12-03 | 2013-10-16 | 阿勒根公司 | 作为鞘氨醇1-磷酸(s1p)受体调节剂的新型肟氮杂环丁烷衍生物 |
| AU2015204572B2 (en) | 2014-01-10 | 2020-07-30 | Inspirna, Inc. | LXR agonists and uses thereof |
| JP7025022B2 (ja) | 2016-01-11 | 2022-02-24 | ザ ロックフェラー ユニバーシティー | 骨髄系由来抑制細胞関連障害の治療のための方法 |
| AU2018373028A1 (en) | 2017-11-21 | 2020-04-30 | Inspirna, Inc. | Polymorphs and uses thereof |
| PL4073025T3 (pl) | 2019-12-13 | 2024-09-16 | Inspirna, Inc. | Sole metali i ich zastosowania |
| WO2022109066A1 (en) * | 2020-11-18 | 2022-05-27 | Southern Research Institute | Compounds for the treatment of acute and chronic kidney disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141080A0 (en) | 1998-07-30 | 2002-02-10 | Japan Tobacco Inc | Disubstituted maleimide derivatives and pharmaceutical compositions containing the same |
| DE69922526T2 (de) | 1998-10-08 | 2005-06-02 | Smithkline Beecham Plc, Brentford | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| EP1224932A4 (en) | 1999-08-20 | 2002-10-16 | Sagami Chem Res | ACTIVE SUBSTANCES TO INHIBIT CELL DEATH |
| GB0008264D0 (en) | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
-
2003
- 2003-07-11 GB GBGB0316232.8A patent/GB0316232D0/en not_active Ceased
-
2004
- 2004-06-29 TW TW093119064A patent/TW200503691A/zh unknown
- 2004-07-05 SA SA4250204A patent/SA04250204B1/ar unknown
- 2004-07-08 KR KR1020067000712A patent/KR20060035748A/ko not_active Withdrawn
- 2004-07-08 AT AT04749150T patent/ATE399777T1/de not_active IP Right Cessation
- 2004-07-08 US US10/564,235 patent/US7432288B2/en not_active Expired - Fee Related
- 2004-07-08 RU RU2006102130/04A patent/RU2006102130A/ru not_active Application Discontinuation
- 2004-07-08 EP EP04749150A patent/EP1646626B1/en not_active Expired - Lifetime
- 2004-07-08 ES ES04749150T patent/ES2308204T3/es not_active Expired - Lifetime
- 2004-07-08 WO PCT/SE2004/001114 patent/WO2005005417A1/en not_active Ceased
- 2004-07-08 CA CA002532056A patent/CA2532056A1/en not_active Abandoned
- 2004-07-08 DE DE602004014773T patent/DE602004014773D1/de not_active Expired - Fee Related
- 2004-07-08 JP JP2006520138A patent/JP2007521312A/ja not_active Withdrawn
- 2004-07-08 CN CNA2004800198411A patent/CN1823061A/zh active Pending
- 2004-07-08 BR BRPI0412472-3A patent/BRPI0412472A/pt not_active IP Right Cessation
- 2004-07-08 MX MXPA06000414A patent/MXPA06000414A/es not_active Application Discontinuation
- 2004-07-08 AR ARP040102419A patent/AR045721A1/es not_active Application Discontinuation
- 2004-07-08 AU AU2004255999A patent/AU2004255999B2/en not_active Ceased
- 2004-07-09 MY MYPI20042745A patent/MY135821A/en unknown
- 2004-07-09 UY UY28408A patent/UY28408A1/es unknown
- 2004-08-07 UA UAA200600272A patent/UA82109C2/uk unknown
-
2005
- 2005-12-22 IL IL172760A patent/IL172760A0/en unknown
-
2006
- 2006-01-05 NO NO20060081A patent/NO20060081L/no not_active Application Discontinuation
- 2006-01-10 ZA ZA200600222A patent/ZA200600222B/en unknown
- 2006-02-09 IS IS8293A patent/IS8293A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004255999A1 (en) | 2005-01-20 |
| UA82109C2 (uk) | 2008-03-11 |
| DE602004014773D1 (de) | 2008-08-14 |
| IS8293A (is) | 2006-02-09 |
| US20060235015A1 (en) | 2006-10-19 |
| BRPI0412472A (pt) | 2006-09-19 |
| SA04250204B1 (ar) | 2008-03-23 |
| GB0316232D0 (en) | 2003-08-13 |
| EP1646626B1 (en) | 2008-07-02 |
| ATE399777T1 (de) | 2008-07-15 |
| UY28408A1 (es) | 2005-02-28 |
| CN1823061A (zh) | 2006-08-23 |
| US7432288B2 (en) | 2008-10-07 |
| CA2532056A1 (en) | 2005-01-20 |
| EP1646626A1 (en) | 2006-04-19 |
| NO20060081L (no) | 2006-02-08 |
| JP2007521312A (ja) | 2007-08-02 |
| AU2004255999B2 (en) | 2007-08-02 |
| MY135821A (en) | 2008-07-31 |
| TW200503691A (en) | 2005-02-01 |
| KR20060035748A (ko) | 2006-04-26 |
| WO2005005417A1 (en) | 2005-01-20 |
| AR045721A1 (es) | 2005-11-09 |
| HK1088320A1 (en) | 2006-11-03 |
| IL172760A0 (en) | 2006-04-10 |
| MXPA06000414A (es) | 2006-03-17 |
| ZA200600222B (en) | 2007-04-25 |
| ES2308204T3 (es) | 2008-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006102130A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| RU2386620C2 (ru) | Производные пиридазин-3(2н)-она и их применение в качестве ингибиторов фдэ4 | |
| JP2007521312A5 (enExample) | ||
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| RU2439068C2 (ru) | Модуляторы mglur5 | |
| RU2375363C2 (ru) | Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы | |
| RU2205827C2 (ru) | Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция | |
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| RU2006102129A (ru) | Производные пиррол-2, 5-дитиона в качестве модуляторов печеночных х-рецепторов | |
| JP2005526723A5 (enExample) | ||
| JP2005538955A5 (enExample) | ||
| JP2005532982A5 (enExample) | ||
| JP2010530438A5 (enExample) | ||
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| RU2004117545A (ru) | Аминопиримидины и пиридины | |
| JP2014511869A5 (enExample) | ||
| JP2005504100A5 (enExample) | ||
| JP2007519754A5 (enExample) | ||
| JP2013516415A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2006524222A5 (enExample) | ||
| RU2005124359A (ru) | Пирролилтиазолы и их применение в качестве обратных агонистов рецептора св 1 | |
| RU2004113207A (ru) | Хинолиновые производные в качестве антагонистов нейропептида y | |
| JP2019537603A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081022 |
|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081022 |